Stage 3a chronic kidney disease is a real diagnosis that deserves attention, but for most people it is not the crisis it sounds like. Your kidneys are working at roughly 45 to 59 percent of their normal filtering capacity, which is enough to keep you feeling fine in most cases, and fewer than one in twenty people at this stage will progress to kidney failure within a decade. The bigger concern, and the one that often gets overlooked, is the elevated risk of cardiovascular problems like heart attack and stroke. Understanding where the actual dangers lie, and what drives them, changes how you think about this diagnosis entirely.
What a Stage 3a Diagnosis Tells You
Kidney disease staging is based on your estimated glomerular filtration rate, or eGFR, which is a blood-test measure of how well your kidneys filter waste. Stage 3a means your eGFR falls between 45 and 59 mL/min per 1.73 square meters of body surface area.1NCBI Bookshelf. Chronic Kidney Disease In plain terms, your kidneys are still doing most of what they need to do, but they have lost enough capacity that a doctor should be monitoring them. The label “chronic kidney disease” itself alarms a lot of people, because it sounds like you are on a one-way road toward dialysis. That is not what the evidence shows for the majority of people at this stage.
Stage 3 is actually the most commonly diagnosed stage of CKD, and a large share of people in it are older adults whose kidney function has declined gradually with age. The distinction between 3a and 3b matters: 3b (an eGFR of 30 to 44) carries a meaningfully higher risk of complications. Stage 3a sits in a gray zone where the kidneys are clearly not performing at full strength, but the decline is modest enough that many people live with it for years without it getting worse.
Why You Probably Don’t Feel Any Different
One of the most confusing things about a stage 3a diagnosis is that you likely had no idea anything was wrong. The National Kidney Foundation notes that stage 3a is when symptoms may start to appear, but typically no symptoms are present.2National Kidney Foundation. Stage G3a Chronic Kidney Disease (CKD) That disconnect between the diagnosis and how you feel can go two ways: some people dismiss the diagnosis because they feel fine, while others spiral into anxiety over what might happen. Neither reaction is particularly useful.
The lack of symptoms does not mean nothing is happening. Your kidneys are still filtering blood, producing urine, and maintaining electrolyte balance, but they are doing it with less margin for error. If you get dehydrated, take medications that stress the kidneys, or develop an acute illness, you have less reserve to handle the hit. The reason doctors flag stage 3a even when you feel well is to start protecting that remaining kidney function before symptoms actually develop. By the time CKD produces noticeable symptoms like fatigue, swelling, or changes in urination, kidney function has usually dropped well below the 3a range.
Heart Disease Is the Bigger Threat
This is probably the most underappreciated fact about stage 3a CKD: the thing most likely to harm you is not kidney failure. It is your heart. Cardiovascular events are already significantly more common in people with early CKD stages, even stages 1 through 3, compared to the general population, and cardiovascular disease rather than end-stage kidney disease is the leading cause of death in this high-risk group.3Circulation. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
The reasons are partly overlapping risk factors. High blood pressure and diabetes are the two biggest drivers of CKD, and both also drive heart disease. But the kidneys themselves play an active role: when they are not filtering efficiently, waste products build up in the blood, inflammation rises, blood vessels stiffen, and the heart has to work harder. Even at stage 3a, these changes have begun. So while it is natural to fixate on whether your kidneys will fail, the more immediate question for most people is whether their blood pressure, blood sugar, and cholesterol are well controlled. Treating those is not just good for general health; it is directly protecting both your kidneys and your heart at the same time.
Albuminuria Changes the Risk Picture Dramatically
If you have stage 3a CKD and your doctor has not checked for protein in your urine, that is a gap worth raising. Albuminuria, meaning the leakage of the protein albumin into urine, is one of the strongest predictors of how CKD will behave over time. Two people can have the exact same eGFR and face very different futures depending on how much protein is spilling into their urine.
A cohort study published in a BMJ journal found that among people with early-stage CKD, the severity of albuminuria had a graded relationship with adverse outcomes, meaning the more protein in the urine, the worse the cardiovascular and kidney prognosis became in a stepwise fashion.4BMJ. Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study This is worth understanding because it means “stage 3a” is not one thing. A person with stage 3a CKD and no albuminuria has a fundamentally different risk profile from someone with stage 3a CKD and heavy protein leakage. The staging number alone does not tell the whole story.
If your urine albumin-to-creatinine ratio is normal or only mildly elevated, your prognosis at stage 3a is considerably more reassuring. If it is moderately or severely elevated, that is a signal your kidneys are under more stress than the eGFR number alone suggests, and it shifts the urgency of treatment. This is one of the clearest places where asking your doctor a specific question, “What is my albuminuria level?” can change how seriously you and your care team treat the diagnosis.
How Likely Is Progression to Kidney Failure
The fear that keeps most people up at night after a stage 3a diagnosis is dialysis. A systematic review of the evidence found that end-stage renal disease was rare in stage 3 CKD, occurring in about 4 percent of patients over ten years, and kidney progression was evident in fewer than one in five patients after five years.5PubMed Central. Does stage-3 chronic kidney disease matter?: A systematic literature review Those numbers are lower than most people expect. They mean that the large majority of people diagnosed at stage 3 will still have stage 3 kidney disease, or better, five years later. A meaningful fraction will never progress at all.
That said, the people who do progress tend to share certain characteristics. Uncontrolled diabetes, persistently high blood pressure, heavy albuminuria, smoking, and recurrent kidney injuries from medications or dehydration all push the disease forward more quickly. If you have none of those risk factors and your eGFR has been stable over repeat lab checks, you are likely in the large group where the disease stays put. If you have several of those risk factors and your eGFR has been trending downward from one visit to the next, the situation is more serious and more active management is warranted.
One common source of confusion: eGFR can fluctuate. A single blood test that reads 57 one month might read 52 three months later and 56 the month after that. That kind of bounce is normal and does not necessarily mean your kidneys are declining. What matters is the trend over a year or more. Ask your doctor to show you your eGFR values plotted over time. A steady line or a slight decline in an older adult is different from a steep downward slope in a 50-year-old with diabetes. Context matters far more than any single number.
Medications That Protect Kidney Function
Stage 3a CKD is early enough that treatment can meaningfully slow or halt further decline. The cornerstone medications are blood pressure drugs called ACE inhibitors and ARBs, which do double duty by lowering blood pressure and reducing the amount of protein leaking into the urine. In recent years, the treatment landscape has expanded significantly. A review in a Springer journal found that five drug classes have demonstrated at least a 30 percent reduction in protein leakage and direct evidence of slowing CKD progression in people with type 2 diabetes and kidney disease: ACE inhibitors, ARBs, SGLT2 inhibitors, GLP-1 receptor agonists, and the mineralocorticoid receptor antagonist finerenone.6SpringerOpen. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
SGLT2 inhibitors, originally developed as diabetes medications, have been a particularly welcome development because they appear to protect the kidneys through mechanisms that go beyond blood sugar control. They reduce pressure inside the kidney’s filtering units and lower inflammation, and major trials have shown benefits even in people without diabetes. If you have stage 3a CKD and are not already on one of these newer medications, it is worth discussing with your doctor whether you are a candidate, especially if you have albuminuria or diabetes.
Medications are only part of the equation. Blood pressure management, dietary sodium reduction, weight control, smoking cessation, and adequate hydration all affect kidney health. None of these are dramatic interventions, but at stage 3a, where the disease has not yet caused serious damage, they can be the difference between a stable kidney function trajectory and a declining one. The frustrating reality of stage 3a CKD is that the things that help most are also the most boring: taking your medications consistently, showing up for lab checks, and managing the chronic conditions that got you here.
When to Push for More Aggressive Monitoring
Not everyone with stage 3a CKD needs the same level of attention. If you are over 70, have a stable eGFR that has barely moved in years, no albuminuria, and well-controlled blood pressure, your doctor may reasonably check your labs once or twice a year and leave it at that. Stage 3a CKD in an older adult with no other risk factors is often more of a monitoring situation than an active treatment problem.
The situation is different if you are younger, have diabetes, have significant albuminuria, or if your eGFR has been dropping by more than a few points per year. In those cases, you should be seeing a nephrologist, not just a primary care doctor. A nephrologist can order more detailed testing, adjust kidney-specific medications, and help coordinate care with your other specialists. Many people with stage 3a CKD are managed entirely in primary care, and for the low-risk majority that is fine. But the evidence on albuminuria and cardiovascular risk suggests that some patients at this stage are being undertreated because the “mild” label lulls both patient and doctor into complacency.
A practical way to think about it: if you have two or more of the following, you should be pushing for a nephrology referral and closer monitoring: diabetes, albuminuria (even moderate), eGFR that has dropped by five or more points over the past year, blood pressure that remains high despite medication, or a family history of kidney failure. If you have none of those, your stage 3a CKD is still worth watching, but the data suggest you are in a genuinely lower-risk category.
What Doctors Sometimes Get Wrong About Stage 3a
There are a few places where the standard messaging around stage 3a CKD can be misleading. The first is the implied progression timeline. Staging systems, by their nature, suggest a sequence: stage 1, then 2, then 3, then 4, then 5 and dialysis. Most people mentally fill in a forward arrow. But the systematic review data make it clear that progression through the stages is the exception, not the rule, especially at stage 3a.5PubMed Central. Does stage-3 chronic kidney disease matter?: A systematic literature review Many people stay at their current stage indefinitely. Some even see eGFR improve if the underlying cause, like uncontrolled blood pressure, is addressed.
The second is the relative silence about cardiovascular risk. When patients hear “kidney disease,” they think about kidneys. But as the evidence shows, cardiovascular disease is the leading cause of death for people with CKD, not kidney failure itself.3Circulation. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options If your doctor spends all of your visit talking about kidney numbers and none of it talking about your heart health, lipid levels, and vascular risk, the conversation is incomplete. Stage 3a CKD should be treated as a cardiovascular risk factor in the same way high cholesterol or a family history of heart disease would be.
Medications to Be Cautious About
One immediate practical consequence of a stage 3a diagnosis that many people overlook is the effect on what medications are safe for you. Nonsteroidal anti-inflammatory drugs, the category that includes ibuprofen and naproxen, can reduce blood flow to the kidneys and accelerate damage. Occasional use of a single dose may be fine for some people, but regular or high-dose use is genuinely risky at this stage. Many people with CKD continue to take over-the-counter painkillers without realizing the kidneys are processing those drugs with less capacity than before.
Certain contrast dyes used in CT scans and other imaging procedures can also stress the kidneys. If you need a scan that involves contrast, make sure the ordering physician knows your eGFR. In most cases, adjustments can be made, like using a lower volume of dye or hydrating you before and after the procedure. The risk is not so high that you should avoid necessary medical imaging, but it is high enough that your kidney function should be part of the conversation.
Some antibiotics and other prescription drugs are cleared by the kidneys and may need dose adjustments at stage 3a. This is less about avoiding medications entirely and more about making sure every prescriber you see, your dentist, your urgent care doctor, your surgeon, knows your eGFR. Keeping a note of your most recent kidney function on your phone is a simple step that can prevent dosing errors. At stage 3a, your kidneys still work well enough to handle most drugs, but the safety margin has narrowed, and every provider in your care needs to know that.